Boston Scientific has launched its Precision Novi spinal cord stimulator (SCS) system for use across Europe.
Having secured CE Mark for the treatment of chronic pain, the 16-contact primary cell device is claimed to be the smallest high-capacity primary cell device currently available.
Powered by Illumina 3D software, the Precision Novi implant is designed for increased comfort for patients with pain treated using primary cell therapy.
The Precision Novi system is also believed to be the only primary cell device that uses a wireless remote, providing patients with flexibility and control over their pain management.
Thurrock University Hospitals Pain Management and Neuromodulation consultant Dr Simon Thomson said: "The small size and novel shape of the Precision Novi implant improves patient comfort and enables a very discreet subcutaneous placement."
The intuitive Illumina 3D neural targeting software incorporates three-dimensional lead location, as well as conductivity of the spinal cord and surrounding tissue unlike any other primary cell system.
The point-and-click technology is capable of automatically calculating the optimal programming configuration to target the selected pain area.
Boston Scientific Neuromodulation president Maulik Nanavaty said: "The Precision Novi system brings the power of our Illumina 3D algorithm to more than 60% of SCS patients in Europe who are treated with primary cell therapy."
Precision Novi is a MultiWave platform that can deliver various field shapes and waveforms with or without paresthesia, including burst and higher rate frequencies.
According to the company, the Precision Novi SCS system is unavailable in the US.